
Neuronetics Inc (STIM) Stock Forecast & Price Target
Neuronetics Inc (STIM) Analyst Ratings
Bulls say
Neuronetics is well-positioned for growth and has potential in the underserved TRD patient population. They have a leading TMS franchise and are expanding their customer base through the acquisition of Greenbrook TMS. Additionally, the company is focused on addressing the demand for non-pharmacologic treatment options in the mental health industry. However, risks such as inconsistent execution, competition, and regulatory delays should be considered.
Bears say
Neuronetics is facing a challenging market with increasing competition and potential pricing pressure as more companies enter the TMS space. Despite positive results from their Phase 3 trials for COMP360, the success and market approval of this product is not guaranteed. Additionally, the company has a history of negative cash flow and may need to raise more capital in the near future.
This aggregate rating is based on analysts' research of Neuronetics Inc and is not a guaranteed prediction by Public.com or investment advice.
Neuronetics Inc (STIM) Analyst Forecast & Price Prediction
Start investing in Neuronetics Inc (STIM)
Order type
Buy in
Order amount
Est. shares
0 shares